Market Overview

The China genetic testing market size reached USD 4.9 Billion in 2024. IMARC Group forecasts the market to expand to USD 16.4 Billion by 2033, growing at a CAGR of 13.68% during the 2025-2033 forecast period. Genetic testing, which involves analysis of chromosomes, genes, or proteins to detect genetic disorders, is increasing in popularity in China due to rising awareness, accessibility of direct-to-consumer tests, and policy changes encouraging births.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

China Genetic Testing Market Key Takeaways

• The China genetic testing market size was USD 4.9 Billion in 2024.
• The market growth rate is expected to be a CAGR of 13.68% during 2025-2033.
• The forecast period spans from 2025 to 2033.
• Prenatal testing is the largest segment by test type.
• Cancer is the dominant segment by disease.
• Biochemical technology currently leads the technology segment.
• Hospital based laboratories hold the largest share among service providers.
• Blood samples predominate the testing sample segment.

Sample Request Link: 

https://www.imarcgroup.com/china-genetic-testing-market/requestsample

Market Growth Factors

Growing awareness regarding the various advantages of the use of genetic testing among the medical community is one of the major factors driving the growth of the market․ The wide use of genetic testing and increasing awareness regarding the role of genetic testing in the early diagnosis and treatment of chronic diseases are expected to increase the demand for genetic testing as a screening tool in the near future․

A further contributor to market growth is the increasing availability, and access, to DTC genetic testing services, whereby the consumer can undertake the genetic test at home․

The universal two-child policy that was enforced in October 2015 replacing the one-child policy is expected to increase the number of births and thereby fuel growth in the newborn genetic testing market․ The growth in the market will come from the growing middle class population and geriatric population, and the growth of healthcare infrastructure․

Market Segmentation

• By Test Type: Prenatal Testing, Carrier Testing, New Born Testing, Predictive/Presymptomatic Testing, Diagnostic Testing, Others
• Prenatal testing represents the largest segment, driven by policy changes increasing newborns.
• By Disease: Cancer, Down Syndrome, Thalassemia, Others
• Cancer holds the dominant market share among the disease segments.
• By Technology: Biochemical, Molecular, Cytogenetic
• Biochemical technology is the leading segment, representing the biggest share.
• By Service Provider: Hospital Based Laboratories, Independent Laboratories, Specialty Clinics
• Hospital based laboratories currently have the largest market share.
• By Testing Sample: Blood, Saliva, Hair, Others
• Blood samples are the predominant testing sample segment.

Request Customization:

https://www.imarcgroup.com/request?type=report&id=1111&flag=E 

Key Players

• BGI
• Berry Genomics Co. ltd.
• Daan Gene Co. Ltd
• WuXi NextCODE
• Annoroad Gene Technology Co. Ltd.
• WuXi PharmaTech

Customization Note:

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302